Abstract
Several vaccine candidates to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) have entered or will soon enter large-scale, phase 3, placebo-controlled randomized clinical trials. To facilitate harmonized evaluation and comparison of the efficacy of these vaccines, a general set of clinical endpoints is proposed, along with considerations to guide the selection of the primary endpoints on the basis of clinical and statistical reasoning. The plausibility that vaccine protection against symptomatic COVID-19 could be accompanied by a shift toward more SARS-CoV-2 infections that are asymptomatic is highlighted, as well as the potential implications of such a shift.
【초록키워드】 COVID-19, coronavirus disease, SARS-CoV-2, Coronavirus disease 2019, Efficacy, Vaccine, coronavirus, Vaccines, SARS-COV-2 infection, Infection, severe acute respiratory syndrome Coronavirus, Clinical endpoints, Asymptomatic, symptomatic, vaccine candidate, Placebo, respiratory, randomized clinical trials, SARS-CoV-2 infections, placebo-controlled, Phase 3, symptomatic COVID-19, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, primary endpoints, shift, implication, statistical, PROTECT, facilitate, accompanied, clinical endpoint, the primary endpoint, 【제목키워드】 COVID-19, clinical, Evaluating,